Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06023186 · ClinicalTrials.gov registry record
Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM
A clinical trial of Obstructive Hypertrophic Cardiomyopathy, sponsored by Michael Ayers.
- Recruiting
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT06023186: Recruiting study of Obstructive Hypertrophic Cardiomyopathy, sponsored by Michael Ayers.
NCT06023186 is a study of Obstructive Hypertrophic Cardiomyopathy that is actively recruiting participants, run by Michael Ayers. The registered enrollment target is 20 participants, below the 681-participant average among 3 other Obstructive Hypertrophic Cardiomyopathy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06023186, a study of Obstructive Hypertrophic Cardiomyopathy, is actively recruiting participants, sponsored by Michael Ayers.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this observational study is to measure the effect of mavacamten treatment on blood flow in the heart muscle (myocardium) in patients with obstructive hypertrophic cardiomyopathy. The main question it aims to answer is: • Does mavacamten treatment improve blood flow in the heart muscle? Participants will take mavacamten at the direction of their treating physician. Participants will complete 2 myocardial Positron Emission Tomography and Computed Tomography (PET-CT) scans. The first scan will be completed before participants start taking mavacamten. The scan will be repeated after 12 months of mavacamten treatment.
Primary Outcome
Myocardial perfusion reserve is the ratio of global myocardial blood flow at stress versus rest.
Conditions Studied
Interventions
- DRUG mavacamten
Study Locations (1)
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-11-03 |
| Est. Completion | 2026-09-30 |
What NCT06023186 shows while recruiting
NCT06023186 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 681-participant average among 3 other Obstructive Hypertrophic Cardiomyopathy trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Obstructive Hypertrophic Cardiomyopathy appearing as the primary indexed condition, and to 1 intervention - of which mavacamten is the first listed.
NCT06023186 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06023186 about?
NCT06023186 is a clinical study titled "Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM". The goal of this observational study is to measure the effect of mavacamten treatment on blood flow in the heart muscle (myocardium) in patients with obstructive hypertrophic cardiomyopathy. The main question it aims to answer is: • Does mavacamten treatment improve blood flow in the heart muscle? ...
What is the current status of trial NCT06023186?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2023-11-03. Estimated completion is 2026-09-30.
What conditions does trial NCT06023186 study?
This clinical trial studies the following conditions: Obstructive Hypertrophic Cardiomyopathy.
What interventions are being tested in trial NCT06023186?
The interventions under investigation include: mavacamten (DRUG).
Who is sponsoring clinical trial NCT06023186?
This trial is sponsored by Michael Ayers, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06023186 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obstructive Hypertrophic Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Real-world Patient Reported Outcomes Among Patients Treated With Camzyos
RECRUITING
-
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
RECRUITING
-
Patients' Long-Term Survival of Obstructive Hypertrophic Cardiomyopathy (HCM)
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI